Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

Fig. 2

TAFIa inhibits pericellular plasminogen activation on breast cancer cell lines. SUM149 (black bars) and MDA-MB-231 cells (grey bars) were treated with varying concentrations of TAFIa (1–50 nM) for 30 min at 37 °C. Plasminogen activation assay was carried out with 300 nM plasminogen, 10 pM uPA and a fluorescent plasmin substrate. The rate of formation of plasmin (taken as the slope of the plot of change in fluorescence versus time squared) was monitored for 1 h at 37 °C. The data represent the means ± SEM of 4–5 independent experiments and are expressed relative to the control in the absence of TAFIa. **: p <0.01 relative to control

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us